Facing ineffectiveness of disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA): Shall DMARDs be switched or be combined?

被引：0
|
作者：
Schoels, M
Kapral, T
Stamm, T
Smolen, JS
Aletaha, D
机构：
[1] Lainz Hosp, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [1] Predictive factors for withdrawal of disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA): Is age relevant?
    Mok, CC
    Ng, WL
    Yim, CW
    Wong, RWS
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S172 - S172
  • [2] A meta-analysis of the efficacy and toxicity of combining disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA).
    Choy, EHS
    Smith, C
    Scott, DL
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S170 - S170
  • [3] Safety of disease modifying anti-rheumatic drugs (DMARDS) in rheumatoid arthritis (RA) patients with chronic viral hepatitis.
    Mok, MY
    Ng, WL
    Wong, RWS
    Lau, CS
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S156 - S156
  • [4] Step-up combination therapy of disease modifying anti-rheumatic drugs (DMARDS) in rheumatoid arthritis (RA) is not superior to switching of DMARDS: Results from an observational study
    Schoels, M.
    Kapral, T.
    Stamm, T.
    Smolen, J. S.
    Aletaha, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 345 - 345
  • [5] The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
    Tan, Chou Luan
    Ng, Boon Han
    Ahmad, Noor Shahrazat
    Soelar, Shahrul Aiman
    Jazlan, Muhammad Zulhilmi Asyraf
    Mansor, Mohd Ammar Dzakirin Md
    Suan, Mohd Azri Mohd
    Kiew, Kuang Kiat
    Zainuddin, Zalwani
    Abu Hassan, Muhammad Radzi
    Lim, Chong Hong
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] Economic analysis of novel disease-modifying anti-rheumatic drugs (DMARDS) for rheumatoid arthritis (RA) patients in a managed care setting
    D'Souza, AO
    Crivera, C
    Doyle, JJ
    VALUE IN HEALTH, 2003, 6 (03) : 222 - 222
  • [7] TREATING EARLY RHEUMATOID ARTHRITIS (RA) INTENSIVELY: UK RHEUMATOLOGISTS VIEWS AND USE OF COMBINATION DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    Garrood, Toby
    Shattles, Warren
    Scott, David L.
    RHEUMATOLOGY, 2009, 48 : I83 - I83
  • [8] MISSED OPPORTUNITIES IN THE MONITORING OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    Dyaanand, H.
    Dickson, M.
    Tilley, D.
    Nisar, M.
    RHEUMATOLOGY, 2002, 41 : 43 - 43
  • [9] Saudi cultural adaptation of the "compliance questionnaire of Rheumatology" for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
    Aljohani, Roaa
    Aljohani, Zeyad
    Aljohani, Rawan
    Alsaidalani, Raghad
    SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (05) : 377 - 383
  • [10] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
12345